P
P. Therasse
Researcher at GlaxoSmithKline
Publications - 24
Citations - 21951
P. Therasse is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Cancer & Adjuvant therapy. The author has an hindex of 14, co-authored 24 publications receiving 17631 citations.
Papers
More filters
Journal ArticleDOI
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
Elizabeth Eisenhauer,P. Therasse,Jan Bogaerts,Lawrence H. Schwartz,Daniel J. Sargent,Robert Ford,Janet Dancey,S. Arbuck,S. Gwyther,Margaret M. Mooney,Larry Rubinstein,Lalitha K. Shankar,Lori E. Dodd,Robert M. Kaplan,Denis Lacombe,Jaap Verweij +15 more
TL;DR: The revised RECIST includes a new imaging appendix with updated recommendations on the optimal anatomical assessment of lesions, and a section on detection of new lesions, including the interpretation of FDG-PET scan assessment is included.
Journal ArticleDOI
Evaluation of lymph nodes with RECIST 1.1.
Lawrence H. Schwartz,Jan Bogaerts,Robert Ford,Lalitha K. Shankar,P. Therasse,S. Gwyther,Elizabeth Eisenhauer +6 more
TL;DR: These standardised lymph node guidelines are designed to be easy to implement, focus target lesion measurements on lesions that are likely to be metastatic and prevent false progressions due to minimal change in size.
Journal ArticleDOI
Individual patient data analysis to assess modifications to the RECIST criteria.
Jan Bogaerts,Robert Ford,Daniel J. Sargent,Lawrence H. Schwartz,Larry Rubinstein,Denis Lacombe,Elizabeth Eisenhauer,Jaap Verweij,P. Therasse +8 more
TL;DR: Assessment of 5 lesions per patient led to a difference in best overall response assignment for an estimated 209 patients as compared to RECIST version 1.0, but removal of the requirement for response confirmation did not affect the overall response rate.
Journal ArticleDOI
32 INVITED New response evaluation criteria in solid tumors: revised RECIST guideline version 1.1
Elizabeth Eisenhauer,P. Therasse,Jan Bogaerts,Lawrence H. Schwartz,Daniel J. Sargent,Robert Ford,Janet Dancey,S. Arbuck,S. Gwyther,M. Mooney,L. Rubenstein,Lalitha K. Shankar,Robert M. Kaplan,Denis Lacombe,Jaap Verweij +14 more
Journal ArticleDOI
Recommendations for the assessment of progression in randomised cancer treatment trials
Janet Dancey,Lori E. Dodd,Robert Ford,Richard Kaplan,Margaret M. Mooney,Larry Rubinstein,Lawrence H. Schwartz,Lalitha K. Shankar,P. Therasse +8 more
TL;DR: Progression-free survival is an increasingly important end-point in cancer drug development, but several concerns exist regarding the use of PFS as a basis to compare treatments.